Medindia

X

Asymchem announces its Initial Public Offering

Friday, November 18, 2016 General News J E 4
Advertisement

SHENZHEN, China, Nov. 18, 2016 /PRNewswire/ -- Asymchem Laboratories (Tianjin) Co., Ltd., a leading contract manufacturer of Active Pharmaceutical Ingredients, today announced its Initial Public Offering (IPO) of 28,215,875 shares of A-share stock at a price of ?30.53 per share. The offering is anticipated to raise approximately ?861.43 million of proceeds, which Asymchem intends to use for existing business. The listing began trading on the Shenzhen Stock Exchange under the symbol "002821".

Dr. Hao Hong, Chairman and CEO of Asymchem said: "I am confident that today marks the beginning of an important and exciting chapter for Asymchem. The driven team that I have the privilege of leading, together with the strengthening of our capital position today, will enable us to make Asymchem a clear leader in CMC contract manufacturing in the pharmaceutical industry worldwide."

"Becoming a listed company is an important milestone for Asymchem, and also a successful example of commercial capital operations support in Tianjin City," said Mr. Qingmin Yan, Deputy Mayor of Tianjin, at the bell ringing ceremony.

About Asymchem GroupAsymchem is a custom synthesis CMC contract manufacturer of cGMP intermediates and API's for the global pharmaceutical industry, providing compliant and sustainable manufacturing solutions worldwide over the lifecycle of a drug. Founded in 1995, USFDA and TGA inspected.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asymchem-announces-its-initial-public-offering-300365917.html

SOURCE Asymchem Laboratories (Tianjin) Co., Ltd.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Optic Neuritis Market key Players Profile and Indu...
S
Tillotts Pharma AG Introduces the New Technology O...